跳至主要内容
临床试验/ACTRN12623000155695
ACTRN12623000155695尚未招募1 期

A pilot study to test the effects of a single microdose of ayahuasca alkaloids on blood pathology of neurotransmitters and inflammation marker levels, safety observations, and mood self-efficacy in healthy adults

Biochem Industries Pty Ltd0 个研究点目标入组 5 人开始时间: 2023年2月16日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
25 Years 至 60 Years(—)
性别
All

入选标准

  • Participant is willing and able to give informed consent for participation in the trial
  • Adults aged 25-60 years inclusive

排除标准

  • Current use of any prescribed psychotropic medication
  • Significant renal or hepatic impairment as judged by study clinicians
  • Cardiovascular conditions including, abnormal heart rate or blood pressure to be checked at screening. A threshold of exceeding 160 mmHg (systolic) and 90 mmHg (diastolic), averaged across four assessments taken on the screening day will be used
  • Any unstable medical or neurologic condition
  • Current or past history diagnosis of schizophrenia or other psychotic disorders, or Bipolar I or II Disorder
  • Imminent risk of suicide
  • Lifetime presence of diagnosis of Major Depressive Disorder not in remission
  • Current diagnosis of panic disorders, OCD, dysthymic disorder, anorexia, or bulimia
  • Body-weight <50 kg or >120 kg
  • Substance dependence diagnosis in the previous three months

研究者

发起方
Biochem Industries Pty Ltd

相似试验